Analysis Torrent Pharmaceuticals Limited (TORNTPHARM)
5/28/2024
Analysis of Torrent Pharmaceuticals Limited (TORNTPHARM)
Torrent Pharmaceuticals Limited has been showing some fluctuations in its stock price recently. The Relative Strength Index (RSI) values have been hovering around the mid-range, indicating a balanced market sentiment. The Moving Average Convergence Divergence (MACD) indicator has shown some positive movements, with the MACD line crossing above the signal line on some days.Overall, the stock seems to be trading within a range, with some volatility in the short term. It would be important to monitor the price levels and key technical indicators for potential trends or signals for future price movements.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. The gross profit margin has been fluctuating, with the highest in 2023 at $169.1 billion and the lowest in 2020 at $105 billion.
3. Operating income has also shown an increasing trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
4. Net income has been on the rise, with the company making $99.8 billion in 2022 and $96.9 billion in 2023.
5. Earnings per share (EPS) have been relatively stable, with slight fluctuations over the years.
6. The company has been able to maintain a healthy EBITDA margin, with the highest at $129.2 billion in 2023.
7. Despite fluctuations in other income and expenses, the company has been able to generate consistent net income from continuous operations.
8. The company has managed its operating expenses effectively, with a slight increase over the years but not at a disproportionate rate compared to the revenue growth.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching the highest value of $365,725,000,000 in 2018.
2. Current assets fluctuate from year to year, with the highest value of $162,819,000,000 in 2019.
3. Non-current assets have been increasing steadily, with the highest value of $234,386,000,000 in 2018.
4. Total liabilities have also been increasing, reaching the highest value of $302,083,000,000 in 2022.
5. Shareholders' equity has been fluctuating, with the highest value of $107,147,000,000 in 2018.
6. The company has been relying more on non-current assets to support its operations over the years.
7. There is a need to closely monitor and manage current liabilities to ensure financial stability.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.44.
Moving on to stock statistics, the company has a short ratio of 1.66, with 15.31 billion float shares and 94.31 million shares shorted. The average 10-day volume is 52.90 million shares, while the average 90-day volume is 62.82 million shares. The company has 15.33 billion shares outstanding, with 5.22% held by insiders and 57.55% held by institutions.
Valuation metrics show a PEG ratio of 26.21, forward PE of 26.21, and trailing PE of 29.43. The enterprise value is $2.95 trillion, with a price to book ratio of 39.18 and price to sales ratio of 7.62. The enterprise to EBITDA ratio is 22.75 and the enterprise to revenue ratio is 7.73. The market capitalization is $2.91 trillion.
The stock price summary includes a beta of 1.26, a 50-day moving average of $173.69, a 200-day moving average of $180.79, a 52-week low of $164.08, a 52-week high of $199.62, and a 52-week change of 8.25%.
Lastly, dividends and splits information shows a payout ratio of 14.93%, with a dividend date of May 16, 2024. The last split date was on August 31, 2020, with a 4-for-1 split. The forward annual dividend rate is $1, with a 5-year average dividend yield of 0.73% and a forward annual dividend yield of 0.53%. The trailing annual dividend rate is $0.97, with a trailing annual dividend yield of 0.51%.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next fiscal year. The average estimates show growth compared to the previous year's EPS figures, indicating optimism among analysts regarding the company's performance.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company over the specified periods.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It is important to note that these are analyst estimates and actual performance may vary.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions regarding the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price of the security is $191.57, which is below the median and average forecasted prices.
MACD of TORNTPHARM
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI